Validation of 4-meter-gait-speed test and 5-repetitions-sit-to-stand test in patients with pulmonary fibrosis: a clinimetric validation study

Ada E M Bloem, Marcel Veltkamp, Martijn A Spruit, Jan W H Custers, Eric W P Bakker, Hanneke M Dolk, Jan C Grutters, Ada E M Bloem, Marcel Veltkamp, Martijn A Spruit, Jan W H Custers, Eric W P Bakker, Hanneke M Dolk, Jan C Grutters

Abstract

Background and objective: Patients with pulmonary fibrosis (PF) have a clear exercise intolerance. The 4-meter-gait-speed (4MGS) test and the 5-repetitions-sit-to-stand (5STS) test are easy, inexpensive and reliable measures of functional performance. Both tests have been validated in healthy adults and patients with chronic obstructive pulmonary disease. 4MGS test and 5STS test have not been studied in patients with PF. Methods: In this cross-sectional clinimetric validation study 51 PF patients conducted in random order the 4MGS test, 5STS test and the 6-min walk test (6MWT) on a single day. Additionally, body weight, height, lean body mass, health-related quality of life, disease severity, handgrip strength, dyspnoea and leg fatigue were assessed. The setting was a tertiary referral center for Interstitial Lung Diseases. Results: Patients had a diagnosis of idiopathic pulmonary fibrosis (IPF, 37%), PF other than IPF (47%), or unclassified (16%). Patients walked 453±111m in six minutes. Moreover, it took the patients 2.0±0.5s to walk 4 m, and 12.0±3.8s for the 5STS test. The 4MGS test (r = 0.77; p<0.01) and the 5STS test (r = -0.41; p<0.01) correlated significantly with the distance walked in 6MWT. Indeed, 4MGS combined with handgrip strength and Medical Research Council dyspnoea grade could explain 75% of the variance in 6MWD. Conclusions: 4-meter-gait-speed and 5-repetitions sit-to-stand are significantly and independently correlated with the 6-minute walk distance in patients with pulmonary fibrosis. Indeed, 4-meter-gait-speed test may serve as a simple initial field test to assess exercise performance in patients with pulmonary fibrosis. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 317-326).

Keywords: 6-minute walk test; exercise and pulmonary rehabilitation; gait; pulmonary fibrosis.

Copyright: © 2018 SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES.

Figures

Fig. 1.
Fig. 1.
Flow chart overview of the study design with main procedures
Fig. 2.
Fig. 2.
Correlations between a) 4-meter gait speed test (4MGS) and 6-minute walk distance (6MWD) and b) 5 repetitions sit-to-stand test (5STS) and 6-minute walk distance (6MWD)

References

    1. Travis WD, Costabel U, Hansell DM, et al. An official american thoracic society/european respiratory society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American journal of respiratory and critical care medicine. 2013;188(6):733–748.
    1. Spruit MA, Singh SJ, Garvey C, et al. An official american thoracic society/european respiratory society statement: Key concepts and advances in pulmonary rehabilitation. American journal of respiratory and critical care medicine. 2013;188(8):e13–e64.
    1. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest. 1999;116(5):1175–1182.
    1. American Thoracic Society, American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2):211–277.
    1. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117.
    1. Holland AE. Exercise limitation in interstitial lung disease - mechanisms, significance and therapeutic options. Chron Respir Dis. 2010;7(2):101–111.
    1. Holland AE, Spruit MA, Troosters T, et al. An official european respiratory society/american thoracic society technical standard: Field walking tests in chronic respiratory disease. Eur Respir J. 2014
    1. du Bois RM, Albera C, Bradford WZ, et al. 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014;43(5):1421–1429.
    1. Bloem AE, Veltkamp M, Custers JW, Dolk HM, Grutters JC, Spruit MA. Within-day test-retest reliability of the 6-min walk test in patients with pulmonary fibrosis. Eur Respir J. 2017;49(2)
    1. Kon SS, Patel MS, Canavan JL, et al. Reliability and validity of 4-metre gait speed in COPD. Eur Respir J. 2013;42(2):333–340.
    1. Bohannon RW. Reference values for the five-repetition sit-to-stand test: A descriptive meta-analysis of data from elders. Percept Mot Skills. 2006;103(1):215–222.
    1. Hillegass E. Walking speed in individuals with cardiovascular and pulmonary dysfunction. Topics in Geriatric Rehabilitation. 2012;28(2):110–112.
    1. DePew ZS, Karpman C, Novotny PJ, Benzo RP. Correlations between gait speed, 6-minute walk distance, physical activity, and self-efficacy in patients with severe chronic lung disease. Respir Care. 2013;58(12):2113–2119.
    1. Nolan CM, Delogu V, Maddocks M, et al. Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: A prospective study. Thorax. 2017
    1. Jones SE, Kon SS, Canavan JL, et al. The five-repetition sit-to-stand test as a functional outcome measure in COPD. Thorax. 2013;68(11):1015–1020.
    1. Ozalevli S, Ozden A, Itil O, Akkoclu A. Comparison of the sit-to-stand test with 6 min walk test in patients with chronic obstructive pulmonary disease. Respir Med. 2007;101(2):286–293.
    1. Karpman C, Lebrasseur NK, Depew ZS, Novotny PJ, Benzo RP. Measuring gait speed in the out-patient clinic: Methodology and feasibility. Respir Care. 2014;59(4):531–537.
    1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
    1. Tomioka H, Imanaka K, Hashimoto K, Iwasaki H. Health-related quality of life in patients with idiopathic pulmonary fibrosis--cross-sectional and longitudinal study. Intern Med. 2007;46(18):1533–1542.
    1. Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: A systematic review. Thorax. 2005;60(7):588–594.
    1. Tzanakis N, Samiou M, Lambiri I, Antoniou K, Siafakas N, Bouros D. Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis. correlation with pulmonary function tests. Eur J Intern Med. 2005;16(2):105–112.
    1. Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J. 2010;36(5):1067–1072.
    1. Gibson AL, Heyward VH, Mermier CM. Predictive accuracy of omron® body logic analyzer in estimating relative body fat of adults. Int J Sport Nutr. 2000;10(2):216–227.
    1. Borg G. Borg’s perceived exertion and pain scales. Human kinetics. 1998
    1. Franssen FM, Rutten EP, Groenen MT, Vanfleteren LE, Wouters EF, Spruit MA. New reference values for body composition by bioelectrical impedance analysis in the general population: Results from the UK biobank. Journal of the American Medical Directors Association. 2014;15(6):448.
    1. Fess E, Moran C. American society of hand therapists: Clinical assessment recommendations. Garner: the Society. 1981
    1. Roberts HC, Denison HJ, Martin HJ, et al. A review of the measurement of grip strength in clinical and epidemiological studies: Towards a standardised approach. Age Ageing. 2011;40(4):423–429.
    1. Spruit MA, Sillen MJ, Groenen MT, Wouters EF, Franssen FM. New normative values for handgrip strength: Results from the UK biobank. J Am Med Dir Assoc. 2013;14(10)
    1. Park JH, Jegal Y, Shim TS, et al. Hypoxemia and arrhythmia during daily activities and six-minute walk test in fibrotic interstitial lung diseases. J Korean Med Sci. 2011;26(3):372–378.
    1. Singh SJ, Puhan MA, Andrianopoulos V, et al. An official systematic review of the european respiratory society/american thoracic society: Measurement properties of field walking tests in chronic respiratory disease. Eur Respir J. 2014
    1. Swigris JJ, Olson AL, Shlobin OA, Ahmad S, Brown KK, Nathan SD. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology. 2011;16(3):439–445.
    1. Karpman C, Benzo R. Gait speed as a measure of functional status in COPD patients. Int J Chron Obstruct Pulmon Dis. 2014;9:1315–1320.
    1. Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: Reference values and determinants. Age Ageing. 1997;26(1):15–19.
    1. Bisca GW, Morita AA, Hernandes NA, Probst VS, Pitta F. Simple lower limb functional tests in patients with chronic obstructive pulmonary disease: A systematic review. Arch Phys Med Rehabil. 2015
    1. Holland AE, Spruit MA, Singh SJ. How to carry out a field walking test in chronic respiratory disease. Breathe (Sheff) 2015;11(2):128–139.
    1. Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J. 1999;14(2):270–274.
    1. Altman DG. Practical statistics for medical research. CRC press. 1990
    1. Beurskens S. Meten in de praktijk. Bohn Stafleu van Loghum. 2008
    1. Meriem M, Cherif J, Toujani S, Ouahchi Y, Hmida AB, Beji M. Sit-to-stand test and 6-min walking test correlation in patients with chronic obstructive pulmonary disease. Ann Thorac Med. 2015;10(4):269–273.
    1. Nolan CM, Maddocks M, Maher TM, et al. Phenotypic characteristics associated with slow gait speed in idiopathic pulmonary fibrosis. Respirology. 2017
    1. Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med. 2009;103(1):117–123.
    1. Flaherty KR, Andrei A, Murray S, et al. Idiopathic pulmonary fibrosis: Prognostic value of changes in physiology and six-minute-walk test. American journal of respiratory and critical care medicine. 2006;174(7):803–809.
    1. King TE, Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. The Lancet. 2011;378(9807):1949–1961.
    1. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: Reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171(10):1150–1157.
    1. Caminati A, Harari S. IPF: New insight in diagnosis and prognosis. Respir Med. 2010;104(Suppl 1):S2–10.
    1. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746–752.
    1. Ley B, Collard HR, King TE., Jr Clinical course and prediction of survival in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine. 2011;183(4):431–440.
    1. Saini G, McKeever T, Braybrooke R, Hubbard R, Jenkins G. S15 FVC or TLCO? impact on treatment following NICE (national institute for health and care excellence) approval of pirfenidone. Thorax. 2013;68(Suppl 3):A11–A11.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다